Menostar: Administer a progestin for 14 days every 6–12 months in women with an intact uterus. ERT is appropriate in women who have undergone a hysterectomy (avoids unnecessary exposure to progestins). When estrogen is used for prevention of osteoporosis, response can be assessed by biochemical...
Estradiol is used to treat menopause symptoms such as hot flashes and vaginal changes, and to prevent osteoporosis (bone loss) in menopausal women. Estradiol is also used to treat low estrogen levels in women with ovarian failure. It is also indicated to treat certain types of breast cancer ...
Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis...
Reduced sex hormone binding globulin and derived free testosterone levels in women with severe acne. Clinical Endocrinology, 1981; 15:87–91. 96. Cullberg, G et al. Effects of a low-dose desogestrel-ethinyl estradiol combination on hirsutism, androgens and sex hormone binding globulin in women ...
Objective To assess the value of different serum E2 cut-off levels for predicting women at risk for ovarian hyperstimulation syndrome (OHSS). Design Retrospective case-control study of a cohort of women undergoing assisted reproduction treatment (ART) over 12 months. Setting Tertiary university ...
Generally, when estrogen therapy is prescribed for a postmenopausal woman with a uterus, a progestin should be considered to reduce the risk of endometrial cancer. A woman without a uterus generally does not need a progestin. In some cases, however, hysterectomized women with a history of endo...
In a multicenter, open-label clinical study by Anderson et al,13 1,006 women who were taking EE 30 µg/LNG 150 µg + EE 10 µg over 12 months kept daily electronic diaries of compliance and bleeding. The percentage of women experiencing intermenstrual bleeding is ...
days (of a 28 day cycle) prevents vertebral bone mass loss in postmenopausal women. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. There is no evidence that estrogen replacement therapy restores bone mass to premenopausal levels...
The long-term effects of adjuvant toremifene(TOR)and anastrozole(ANA)on serum follicle-stimulating hormone(FSH)and estradiol(E2)levels in Japanese women were examined using data from a prospective randomized study that mainly studied serum lipids and bone metabolism for 2 years. The study medications...
The greatest risk appears associated with prolonged use—with increased risks of 15- to 24- fold for five to ten years or more—and this risk persists for 8 to over 15 years after estrogen therapy is discontinued. Clinical surveillance of all women taking estrogen/progestin combinations is ...